BEBT-733
BEBT-733 is specifically designed to deliver EGLN1-targeting siRNA to PTECs, aims to reduce hypoxia-inducible factor (HIF) degradation, and mitigates kidney injury and anemia. In an acute kidney injury (AKI) model, a single 5 mg/kg dose reduced EGLN1 mRNA levels by approximately 66.6% and improved serum creatinine and urea levels. In a chronic kidney disease (CKD) model, it improved hemoglobin (HGB) and hematocrit (HCT) levels.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号